Epidemiological and clinical presentations of hospitalized COVID-19 patients in Libya: An initial report from Africa.
Africa
Comorbidity
Coronavirus
Epidemiology
Respiratory distress syndrome
Severe acute respiratory syndrome
Journal
Travel medicine and infectious disease
ISSN: 1873-0442
Titre abrégé: Travel Med Infect Dis
Pays: Netherlands
ID NLM: 101230758
Informations de publication
Date de publication:
Historique:
received:
17
05
2020
revised:
11
04
2021
accepted:
12
04
2021
pubmed:
21
4
2021
medline:
5
8
2021
entrez:
20
4
2021
Statut:
ppublish
Résumé
The first case of the novel coronavirus disease 2019 (COVID-19) in Libya was diagnosed in March 2020. We aimed to determine the epidemiological, clinical, and laboratory characteristics of COVID-19 in Libya. In this retrospective descriptive study, we analyzed the demographics, initial clinical presentation, history, comorbidities, laboratory findings, complications, and outcomes of hospitalized patients with COVID-19 at several centers in the Western part of Libya between March 24, 2020, and December 3, 2020. The study included 811 (67.2%) men and 396 (32.8%) women. The median (interquartile range [IQR]) age was 56 (40-64). A total of 173 (14.3%) patients developed respiratory distress syndrome, while 70 (5.8%) developed circulatory shock and hypotension; 190 (15.7%) were admitted to the intensive care unit. Acute cardiac injury occurred in 27 (2.2%) patients, and 45 (3.7%) developed arrhythmia. Acute kidney injury occurred in 44 (3.6%) patients. Of the patients admitted during the study period, 149 (12.3%) died. The predominant comorbidities ordered in a descending manner were as follows; diabetes mellitus, presented 490 (40.6%), hypertension in 414 (34.3%), chronic kidney disease in 114 (9.4%), and lung diseases in 103 (8.5%). The total white blood cell, neutrophil; monocyte; D-dimer; creatinine kinase; creatine kinase-MB; creatinine; total bilirubin; alanine and aspartate aminotransferase; and hypersensitive troponin were increased among non-survivors, whereas lymphocyte and platelet counts were decreased among non-survivors. This is the first report of the clinical presentations and laboratory findings in patients hospitalized with COVID-19 in Libya. Libyan authorities must implement several restrictions to control the pandemic. However, incoming international travelers pose a challenge to the local authorities, especially with the recent discovery of new variants.
Sections du résumé
BACKGROUND
The first case of the novel coronavirus disease 2019 (COVID-19) in Libya was diagnosed in March 2020. We aimed to determine the epidemiological, clinical, and laboratory characteristics of COVID-19 in Libya.
METHOD
In this retrospective descriptive study, we analyzed the demographics, initial clinical presentation, history, comorbidities, laboratory findings, complications, and outcomes of hospitalized patients with COVID-19 at several centers in the Western part of Libya between March 24, 2020, and December 3, 2020.
RESULTS
The study included 811 (67.2%) men and 396 (32.8%) women. The median (interquartile range [IQR]) age was 56 (40-64). A total of 173 (14.3%) patients developed respiratory distress syndrome, while 70 (5.8%) developed circulatory shock and hypotension; 190 (15.7%) were admitted to the intensive care unit. Acute cardiac injury occurred in 27 (2.2%) patients, and 45 (3.7%) developed arrhythmia. Acute kidney injury occurred in 44 (3.6%) patients. Of the patients admitted during the study period, 149 (12.3%) died. The predominant comorbidities ordered in a descending manner were as follows; diabetes mellitus, presented 490 (40.6%), hypertension in 414 (34.3%), chronic kidney disease in 114 (9.4%), and lung diseases in 103 (8.5%). The total white blood cell, neutrophil; monocyte; D-dimer; creatinine kinase; creatine kinase-MB; creatinine; total bilirubin; alanine and aspartate aminotransferase; and hypersensitive troponin were increased among non-survivors, whereas lymphocyte and platelet counts were decreased among non-survivors.
CONCLUSION
This is the first report of the clinical presentations and laboratory findings in patients hospitalized with COVID-19 in Libya. Libyan authorities must implement several restrictions to control the pandemic. However, incoming international travelers pose a challenge to the local authorities, especially with the recent discovery of new variants.
Identifiants
pubmed: 33878449
pii: S1477-8939(21)00105-8
doi: 10.1016/j.tmaid.2021.102064
pmc: PMC8053220
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102064Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Travel Med Infect Dis. 2020 May - Jun;35:101671
pubmed: 32304743
Sci Rep. 2020 Nov 13;10(1):19765
pubmed: 33188232
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Travel Med Infect Dis. 2021 Mar-Apr;40:101995
pubmed: 33631340
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Lab Med. 2021 Jan 4;52(1):10-15
pubmed: 32929506
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Lancet Haematol. 2020 Sep;7(9):e671-e678
pubmed: 32659214
Disaster Med Public Health Prep. 2021 Aug;15(4):e26-e27
pubmed: 33070803
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Travel Med Infect Dis. 2021 Mar-Apr;40:101977
pubmed: 33486055
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Arch Acad Emerg Med. 2020 Sep 19;8(1):e75
pubmed: 33134971
Travel Med Infect Dis. 2020 Sep-Oct;37:101673
pubmed: 32311437
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Travel Med Infect Dis. 2020 Sep - Oct;37:101652
pubmed: 32247929
Pathobiology. 2021;88(1):15-27
pubmed: 33049751
BMJ. 2020 Mar 17;368:m1066
pubmed: 32184233
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Rev Esp Enferm Dig. 2021 Feb;113(2):125-135
pubmed: 33267597
bioRxiv. 2021 Mar 01;:
pubmed: 33501446
Travel Med Infect Dis. 2020 Sep - Oct;37:101705
pubmed: 32360409
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
PLoS One. 2021 Mar 18;16(3):e0248671
pubmed: 33735911
Travel Med Infect Dis. 2021 Jul-Aug;42:102027
pubmed: 33757850
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
Am J Trop Med Hyg. 2020 Aug;103(2):828-833
pubmed: 32563273
Travel Med Infect Dis. 2021 May-Jun;41:102021
pubmed: 33716170
Infect Dis Health. 2020 Nov;25(4):227-232
pubmed: 32631682
Afr J Emerg Med. 2017 Jun;7(2):47-50
pubmed: 30456107
Lancet. 2018 Mar 3;391(10123):824-825
pubmed: 29508734
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Diabetes Metab Syndr. 2021 Mar-Apr;15(2):529-534
pubmed: 33668003
Biomarkers. 2020 Dec;25(8):626-633
pubmed: 32981387
J Infect Dis. 2021 Aug 2;224(3):395-406
pubmed: 33493287
Travel Med Infect Dis. 2021 Mar-Apr;40:101996
pubmed: 33631338
Ann Surg. 2021 Aug 1;274(2):396-402
pubmed: 32282379
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632